medRxiv PreprintsInternational18 November 2026
Genome-resolved metagenomics reveals population-dependent gut microbiome responses to albendazole-ivermectin treatment
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Soil-transmitted helminth control relies on mass anthelmintic treatment, yet helminth-anthelmintic-microbiome interactions and their role on treatment response remain poorly understood. We characterised the microbiome, resistome, and functional profiles of 858 paired stool metagenomes from 429 children treated with albendazole or a fixed-dose albendazole-ivermectin co-formulation in the ALIVE clinical trial in Ethiopia and Mozambique. Baseline microbiome composition differed more by country than infection status and was not associated with albendazole efficacy or adverse events. Co-formulation
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.